DrugPatentWatch Database Preview
Drugs in Development Information for Alisertib
» See Plans and Pricing
What is the development status for investigational drug Alisertib?
Alisertib is an investigational drug.
There have been 49 clinical trials for Alisertib.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2012.
The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI), and M.D. Anderson Cancer Center.
There are eighteen US patents protecting this investigational drug and two hundred and twenty-three international patents.
Summary for Alisertib
| US Patents | 18 |
| International Patents | 223 |
| US Patent Applications | 42 |
| WIPO Patent Applications | 513 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2012-06-01) |
| Vendors | 73 |
Recent Clinical Trials for Alisertib
| Title | Sponsor | Phase |
|---|---|---|
| Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer | M.D. Anderson Cancer Center | Phase 1/Phase 2 |
| Osimertinib With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer | National Cancer Institute (NCI) | Phase 1 |
Clinical Trial Summary for Alisertib
Top disease conditions for Alisertib
Top clinical trial sponsors for Alisertib
US Patents for Alisertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Alisertib | Start Trial | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-D][2]benzazepin-2-YL]amino}-2-methoxybenzoate | Millennium Pharmaceuticals, Inc. (Cambridge, MA) | Start Trial |
| Alisertib | Start Trial | Combinations of LSD1 inhibitors for use in the treatment of solid tumors | Oryzon Genomics, S.A. (Madrid, ES) | Start Trial |
| Alisertib | Start Trial | Combination of aurora kinase inhibitors and anti-CD30 antibodies | Millennium Pharmaceuticals, Inc. (Cambridge, MA) | Start Trial |
| Alisertib | Start Trial | Combination of aurora kinase inhibitors and anti-CD20 antibodies | Millennium Pharmaceuticals, Inc. (Cambridge, MA) | Start Trial |
| Alisertib | Start Trial | Tetrazolones as a carboxylic acid bioisosteres | Rigel Pharmaceuticals, Inc. (South San Francisco, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Alisertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Alisertib | Brazil | BR112012020557 | 2030-02-19 | Start Trial |
| Alisertib | Canada | CA2788774 | 2030-02-19 | Start Trial |
| Alisertib | China | CN102770024 | 2030-02-19 | Start Trial |
| Alisertib | China | CN104031049 | 2030-02-19 | Start Trial |
| Alisertib | European Patent Office | EP2536279 | 2030-02-19 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
